Indegene

Indegene Launches NEXT Medical Writing Automation to Streamline Complex Medical Writing Workflows with GenAI

Princeton, US - Indegene, a digital-first, life sciences commercialization company, today announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) to accelerate the creation of high-quality, compliant documents across clinical development, regulatory submissions, and beyond. Medical writing teams are under constant pressure to deliver...

BioPharma Industry Excited about the early use of AI in clinical trials

Experts discuss the long road for complete AI-led transformation at Indegene Digital Summit 202421 October 2024 -- New Jersey, US, and London, UK -- Clinical development experts from Novartis, GSK, Bayer and Johnson & Johnson called out the preliminary success indicators of AI adoption in designing and monitoring clinical trials during a panel discussion on...

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

27 March 2024 -- Princeton, US, and Frankfurt, Germany -- Indegene, a digital-first, life sciences commercialisation company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene...
Indegene, Inc. 150 College Rd W Suite 104 Princeton NJ 08540

+1 732 750 2901